Android app on Google Play

Pacira Pharma's (PCRX) Exparel Could Be $1 Billion Product

November 16, 2012 1:44 PM EST Send to a Friend
Get Alerts PCRX Hot Sheet
Price: $66.05 --0%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade PCRX Now!
Join SI Premium – FREE
Pacira Pharmaceuticals (NASDAQ: PCRX) presented at Jefferies' London conference. During the presentation, it highlighted strong momentum in November Exparel sales.

"The stock pulled back as Q3 sales of $4.6M were a little light, but now seems an ideal re-entry point," said analyst Corey Davis.

During the presentation, Pacira made the point that a 10 percent penetration of the 40 million relevant surgical procedures would make Exparel a $1 billion product.

Jefferies has a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX) with a price target of $22.00.

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $15.27 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Jefferies & Co

Add Your Comment